What changed
This royal decree creates a structured, coordinated system for evaluating health technologies — including medicines, medical devices, diagnostics, clinical procedures, and digital health tools — before decisions are made about their public funding, pricing, or withdrawal from Spain's National Health System (SNS). Evaluations must cover both clinical aspects (safety, efficacy) and non-clinical aspects (costs, ethics, social and environmental impact). The framework aligns Spain's national process with EU Regulation 2021/2282 on joint clinical assessments.
Who is affected
This primarily affects national and regional health authorities, the Spanish Medicines Agency (AEMPS), the network of health technology assessment agencies (RedETS), and companies that develop or market health technologies in Spain. Patients, people with disabilities, rare disease communities, and carers are also directly involved, as the law guarantees their participation in the assessment process.
What to look out for
→ No action is required from patients or the general public. It may be worth knowing that funding decisions for new treatments and technologies within the SNS will now follow a more transparent, science-based, and participatory process — official information is available through the Ministry of Health (Ministerio de Sanidad).
⚠️ This explanation was created with AI assistance and may be inaccurate or incomplete. It is not legal advice. Before taking action, check the official text and consult a qualified lawyer.
Original law: BOE-A-2026-11587 — Check the official text before relying on this explanation.